Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMASPWR)

• Drug Name: CM-2395 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMASPWR

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[3]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[4]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[4]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[5]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[6]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[7]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[8]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[9]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[9]
Pfizer 10	DM6ER9L	Female sexual arousal dysfunction	HA01.1	Phase 1	[10]

Drug(s) Targeting Dopamine D4 receptor (D4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[4]
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[11]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[6]
L-745,870	DMTGR25	Psychotic disorder	6A20-6A25	Phase 2	[12]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[13]
ABT-724	DMDQVY4	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[14]
Lu-35138	DMQ7A35	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[15]
NGD-94-4	DMZ9WLO	Schizophrenia	6A20	Discontinued in Phase 1	[16]
PD-165167	DMD0GB4	Schizophrenia	6A20	Preclinical	[13]
SPI-376	DMC1WAJ	Schizophrenia	6A20	Preclinical	[13]

Drug(s) Targeting Opioid receptor sigma 1 (OPRS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[17]
Dextromethorphan Polistirex	DMEHCY5	Dry cough	MD12	Approved	[4]
AVP-786	DMV1SOR	Alzheimer disease	8A20	Phase 3	[18]
ADX N05	DMLBYRA	Mood disorder	6A60-6E23	Phase 3	[19]
Igmesine	DMH97XA	Major depressive disorder	6A70.3	Phase 2	[20]
OPC-14523	DMB1WF3	Bulimia nervosa	6B81	Phase 2	[21]
ANAVEX 2-73	DM67OU4	Alzheimer disease	8A20	Phase 1	[22]
SSR-125047	DMSUFW6	Schizophrenia	6A20	Phase 1	[13]
SA-5845	DM6XZRL	Central nervous system disease	8A04-8D87	Phase 1	[23]
SSR-125329A	DMG6NI8	Immune System disease	4A01-4B41	Phase 1	[24]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[4]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[25]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[26]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[27]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[3]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[28]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[29]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[30]
Treximet	DMU54QB	Migraine	8A80	Approved	[9]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Agonist	[2]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Agonist	[2]
Dopamine D4 receptor (D4R)	TTE0A2F	DRD4_HUMAN	Agonist	[2]
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Agonist	[2]

References

• [1] Pharmaceutical Research Companies Are Developing More Than 300 Medicines to Treat Mental Illnesses. Pharmaceutical Research and Manufacturers of America report.2010.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [3] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [9] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [10] Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
• [11] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [12] Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
• [13] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [14] Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
• [16] I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
• [17] Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
• [18] Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
• [19] Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
• [20] Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
• [21] Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
• [22] 2011 Pipeline of Anavex.
• [23] Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.
• [24] SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31.
• [25] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [26] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [27] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [28] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [29] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [30] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [31] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.